Holen Sie sich die Stockscreener-App
750.57
0.61%
4.57
Schlusskurs vom Vortag:
$746.00
Offen:
$754.74
24-Stunden-Volumen:
512.96K
Relative Volume:
0.72
Marktkapitalisierung:
$79.35B
Einnahmen:
$14.34B
Nettoeinkommen (Verlust:
$4.50B
KGV:
18.06
EPS:
41.5626
Netto-Cashflow:
$3.77B
1W Leistung:
+0.23%
1M Leistung:
-1.12%
6M Leistung:
+29.85%
1J Leistung:
+33.28%
1-Tages-Spanne:
$746.91
$758.61
1-Wochen-Bereich:
$737.34
$760.58
52-Wochen-Spanne:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Firmenname
Regeneron Pharmaceuticals Inc
Sektor
Branche
Telefon
(914) 847-7000
Adresse
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
ARGX
Argen X Se Adr
|
849.04 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2026-03-06 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | BofA Securities | Underperform → Buy |
| 2025-12-03 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Eingeleitet | HSBC Securities | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-14 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Herabstufung | Argus | Buy → Hold |
| 2025-05-30 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-09-24 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Eingeleitet | Bernstein | Outperform |
| 2024-01-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Bestätigt | Oppenheimer | Perform |
| 2023-06-28 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-23 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Hochstufung | Cowen | Market Perform → Outperform |
| 2023-01-20 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Hochstufung | Jefferies | Underperform → Hold |
| 2022-09-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Eingeleitet | Jefferies | Underperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-01-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-12-07 | Fortgesetzt | Cowen | Market Perform |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2021-11-05 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-01-25 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-10-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Hochstufung | SunTrust | Hold → Buy |
| 2020-05-26 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-17 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Eingeleitet | The Benchmark Company | Hold |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Hochstufung | Jefferies | Hold → Buy |
| 2020-02-11 | Hochstufung | Argus | Hold → Buy |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-16 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Eingeleitet | SunTrust | Hold |
| 2019-11-07 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
Alle ansehen
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
Asset Management One Co. Ltd. Sells 6,358 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Understanding Momentum Shifts in (REGN) - Stock Traders Daily
Lbp Am Sa Sells 12,873 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Assetmark Inc. Sells 9,539 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Mirae Asset Global Investments Co. Ltd. Purchases 14,635 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Rx Rundown: Regeneron, AstraZeneca, Revolution Medicines and more - Medical Marketing and Media
KBC Group NV Buys 4,953 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Cwm LLC Grows Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Regeneron’s Dupixent Win And Telix Deal Add New Layers To Valuation - simplywall.st
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), McKesson (MCK) and Regeneron (REGN) - The Globe and Mail
Lobbying Update: $90,000 of REGENERON PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
A Look At Regeneron Pharmaceuticals (REGN) Valuation After New Telix Radiopharmaceutical Collaboration - simplywall.st
Regeneron Pharmaceuticals Inc (REGN) Stock Price, Trades & News - GuruFocus
Telix Pharmaceuticals to collaborate with Regeneron on cancer therapies - Indianapolis Business Journal
Inside Biotech: Telix rally meets reality check as $600m raise tempers Regeneron-driven surge - Proactive Investors
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumine Investment Management, LLC's Regeneron Pharmaceuticals Inc(REGN) Holding History - GuruFocus
Regeneron Boosts Cancer Pipeline Through Telix Collaboration - Yahoo Finance
A $2.1 Billion Radiopharmaceutical Collaboration, Explained - PharmTech.com
Third View Private Wealth Boosts Regeneron Pharmaceuticals Stake - National Today
Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report - Barchart.com
Third View Private Wealth LLC Acquires Shares of 7,149 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Why Telix Pharmaceuticals (ASX:TLX) Is Up 13.8% After Regeneron Radiopharma Alliance Announcement And What’s Next - Yahoo Finance
Novo teams with OpenAI; Ideaya gets muted response to eye drug data - Yahoo Finance
Is It Too Late To Consider Regeneron (REGN) After Its 31% One‑Year Rally? - simplywall.st
Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria - WebWire
Regeneron (REGN) Partners with Telix Pharmaceuticals for Innovat - GuruFocus
Regeneron Pharmaceuticals Inc stock (US7739031091): Is Eylea dominance still the real growth engine? - AD HOC NEWS
Telix And Regeneron Pharmaceuticals Partner To Advance Next Generation Radiopharmaceutical Therapies - BioPharma APAC
Regeneron Pharmaceuticals (REGN) Partners with Telix for Radioph - GuruFocus
Regeneron and Telix reveal radiopharm collab - The Pharma Letter
Regeneron enters radiopharma space via Telix deal - BioWorld News
Regeneron Enters $2.1 Billion Radiopharma Collaboration with Telix Pharmaceuticals - Pharmaceutical Executive
Regeneron, Telix Enter Strategic Radiopharma Collaboration - Contract Pharma
SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria - Yahoo Finance Singapore
The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026 - FinancialContent
Regeneron enters radiopharma ring with up to $4.3B Telix alliance - BioSpace
Telix Pharma Gains As Regeneron Tie-Up Targets Solid Tumor Programs - Benzinga
Regeneron, Sanofi Get Expanded Europe OK for Dupixent in Younger Children With CSU - National Today
Regeneron (REGN) Partners with Telix Pharmaceuticals - GuruFocus
H.C. Wainwright reiterates Telix stock rating on Regeneron deal - Investing.com
Regeneron, Telix partner on radiopharmaceutical cancer therapies By Investing.com - Investing.com Canada
Telix and Regeneron sign $4.3bn deal to co-develop radiopharmaceutical therapies - Yahoo Finance
Regeneron, Telix partner on radiopharmaceutical cancer therapies - Investing.com
Regeneron and Telix Announce Strategic Radiopharma Collaboration - The Manila Times
Telix and Regeneron Announce Strategic Radiopharma Collaboration - Yahoo Finance
Sumitomo Mitsui Trust Group Inc. Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Burney Co. Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN - National Today
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU) - National Today
Finanzdaten der Regeneron Pharmaceuticals Inc-Aktie (REGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Regeneron Pharmaceuticals Inc-Aktie (REGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RYAN ARTHUR F | Director |
Mar 02 '26 |
Sale |
785.50 |
100 |
78,550 |
17,703 |
| Zoghbi Huda Y | Director |
Feb 19 '26 |
Option Exercise |
376.69 |
1,638 |
617,018 |
3,341 |
| Zoghbi Huda Y | Director |
Feb 19 '26 |
Sale |
781.33 |
1,638 |
1,279,812 |
1,703 |
2.50%
3.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):